UNSPSC 51132209: Acetaminophen/butalbital

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51132209 Acetaminophen/butalbital is a Commodity code that describes single pharmaceutical products, but recent state and local solicitations tagged with this code actually encompass broader pharmaceutical procurement—naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products. State and local governments buying under this code include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that distribute pharmaceuticals to public facilities. The scope spans standalone product purchases for community health initiatives (such as naloxone for opioid response), exploratory market research on pharmaceutical supply chain restructuring, and large-scale generic drug and OTC product contracting that requires compliance with Good Manufacturing Practices, the Drug Supply Chain Security Act, and FDA requirements.

Recent activity includes Seminole County, Florida's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) soliciting 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county's community health building; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers to participating state and local government facilities in Minnesota and Oregon. MMCAP's RFP, the largest by scope, requires vendors to achieve a July 1, 2026 contract start with a two-year initial term and emphasizes price competitiveness (75 percent of evaluation weight) alongside manufacturing certifications and EDI capability. Geographic activity concentrates in Florida, Texas, and the Upper Midwest, with multistate cooperative purchasing vehicles extending reach across multiple jurisdictions.